Healthcare Market Research Reports & Industry Analysis

Publications found: 73,128
Sort by:

2015 Strategies in the French Hospital Infectious Disease Testing Market

US$ 3,560.00

... comprehensive analysis of the French hospital infectious disease testing market, including: Major issues pertaining to the French hospital laboratory practice, ... know-how, new products in R&D, collaborative arrangements and business strategies. Business opportunities and strategic recommendations for suppliers. ...

May 2015 897 pages

2015 Strategies in the German Hospital Infectious Disease Testing Market

US$ 3,560.00

... comprehensive analysis of the German hospital infectious disease testing market, including: Major issues pertaining to the German hospital laboratory practice, ... know-how, new products in R&D, collaborative arrangements and business strategies. Business opportunities and strategic recommendations for suppliers. ...

May 2015 897 pages

2015 Strategies in the Italian Hospital Infectious Disease Testing Market

US$ 3,560.00

... comprehensive analysis of the Italian hospital infectious disease testing market, including: Major issues pertaining to the Italian hospital laboratory practice, ... -how, new products in R&D, collaborative arrangements and business strategies. Business opportunities and strategic recommendations for suppliers. ...

May 2015 887 pages

2015 Strategies in the Japanese Hospital Infectious Disease Testing Market

US$ 4,640.00

... comprehensive analysis of the Japanese hospital infectious disease testing market, including: Major issues pertaining to the Japanese hospital laboratory practice, ... -how, new products in R&D, collaborative arrangements and business strategies. Business opportunities and strategic recommendations for suppliers. ...

May 2015 891 pages

2015 Strategies in the Spanish Hospital Infectious Disease Testing Market

US$ 3,560.00

... comprehensive analysis of the Spanish hospital infectious disease testing market, including: Major issues pertaining to the Spanish hospital laboratory practice, ... -how, new products in R&D, collaborative arrangements and business strategies. Business opportunities and strategic recommendations for suppliers. ...

May 2015 880 pages

2015 Strategies in the UK Hospital Infectious Disease Testing Market

US$ 3,560.00

... , technological know-how, new products in R&D, collaborative arrangements and business strategies. Business opportunities and strategic recommendations for suppliers. Contains 886 ...

May 2015 886 pages

2015 Strategies in the US Hospital Infectious Disease Testing Market

US$ 5,440.00

... , technological know-how, new products in R&D, collaborative arrangements and business strategies. Business opportunities and strategic recommendations for suppliers. Contains 997 ...

May 2015 997 pages

mHealth Market by Devices (Blood Glucose Meters, BP Monitors, Pulse oximetry, Neurological Monitoring, Wearable fitness sensor device and Heart Rate Meters), Services (Diagnosis, Monitoring, Prevention, Treatment, Wellness and healthcare system) and Application (Cardiovascular, Diabetes, Respiratory, Neurological) - Global Opportunity Analysis and Industry Forecast, 2014 - 2020

US$ 5,639.00

... Mhealth market on the basis of devices, services, stakeholders, and therapeutic areas. Mhealth device market would be dominated by Blood Glucose Meters, device market and cardiac monitoring devices ... mobile health (mHealth) market as below: Global Mobile Health Market - by Equipment Blood Glucose Meters BP ...

May 2015 157 pages

Global E-Clinical Solutions Market Outlook 2020

US$ 1,000.00

... and growing number of clinical trials and it is estimated to grow at a CAGR of around 15% during 2015-2020. In the report “Global E-Clinical Solutions Market Outlook 2020”, RNCOS’ analysts have identified and described the market dynamics in important segments thus clearly ...

May 2015 75 pages

Market Access Excellence for Emerging Markets

US$ 2,100.00

... access in critical emerging markets? With 12 in-depth case studies, Market Access Excellence for Emerging Markets analyses the pricing and market access issues you must understand now in critical, high-growth markets ... . FirstWord’s Market Access Excellence for Emerging Markets report summarises them, analyses them and prepares you to meet them. Key Benefitss Know which types of markets offer ...

May 2015 -

Building Strong Cross-Functional Medical Affairs Teams

US$ 595.00

Could your Medical Affairs team be better integrated for more effective cross-functional working that drives performance improvement? Building Strong Cross-functional Medical Affairs Teams examines how numerous pharma companies are working to leverage the potential of Medical Affairs in today ...

May 2015 -

Global Hemophilia Market Report: 2015 Edition

US$ 800.00

... others. The report provides a comprehensive study of hemophilia market globally and also provides detailed information for key regional markets. The competition in the global hemophilia market is intense among ...

April 2015 51 pages

Physician Views: Will generic Copaxone have traction in the MS market given emergence of oral therapies?

US$ 695.00

... generic Copaxone may cause some healthcare providers in the US to promote injectable therapies over more expensive oral alternatives. This week's FirstWord Physician Views poll will ask US-based neurologists: What percentage of Copaxone patients they anticipate switching to a three-times ...

April 2015 -

Physician Views: What does the future hold for new EGFR targeting NSCLC therapies?

US$ 695.00

... status – will be presented at next year's ASCO meeting. To gain better physician insight on the potential future role of these two therapies, FirstWord ... ahead of current EGFR therapies such as Tarceva based on current data? What progression-free survival (PFS) benefit CO-1686 would have to demonstrate ...

April 2015 -

Physician Views: Can the launch of ViiV Healthcare's dolutegravir disrupt Gilead's dominance in the HIV market?

US$ 695.00

... status as a seemingly best-in-class integrase inhibitor, there is a chance that physicians could use dolutegravir primarily in Isentress failure patients (similarly as to how ... . To help gauge a more accurate view on how dolutegravir may shape the HIV market, this week's Physician Views poll will ask US-based infectious ...

April 2015 -

Physician Views: How do neurologists value multiple sclerosis medical affairs teams – what could they be doing better?

US$ 695.00

... and value of these teams. FirstWord's latest Physician Views poll seeks to gain some insight into how neurologists value the role that medical affairs personnel in the multiple sclerosis market play. Specifically we asked US and EU5-based doctors: How ...

April 2015 -

Physician Views: With Januvia Data looming, What Impact Will FDA AdComm Have on Use of DPP-IV Inhibitors?

US$ 695.00

... suggest could gain an increased share of the market should physicians shy away from Januvia, Onglyza and/or Nesina. To gain better understanding about ... of heart failure to labels for Onglyza and Nesina. With data from a cardiovascular (CV) outcomes trial of Januvia still to come (expected in June), what impact ...

April 2015 -

Physician Views: Can Intarcia's Implantable GLP-1 Treatment Revolutionise the Diabetes Market?

US$ 695.00

Intarcia has previously suggested that it is the highest-valued privately owned ... ITCA 650 signed with Servier last year, through which Intarcia received a $171 million upfront payment, with a further $880 million ... that the mini-pump is not viewed by everyone as only having niche potential; as another KOL noted, many physicians in the field are likely ...

April 2015 -

Outlook for Hemodialysis Industry in China 2015-2050

US$ 3,500.00

... understanding of global and China’s hemodialysis industry; To analyze major suppliers of hemodialysis products in global and China; To disclose market size of global and China’s hemodialysis industry; To discuss influence ... of China’s hemodialysis industry in the world; To predict what future of China’s hemodialysis industry will be; To reveal opportunities in China’s hemodialysis industry. 2) Benefit from the report Obtain latest info of hemodialysis ...

April 2015 200 pages

Indian IVF Market Outlook 2020

US$ 1,000.00

... ’ report “Indian IVF Market Outlook 2020”, the Indian IVF market is poised to witness impressive CAGR of around 15% from 2014 to 2020. The report offers a detailed study of the overall IVF industry in India. It analyzes ... ; and infertile patients flow to IVF clinics. The market outlook section in the report descriptively discusses the Indian IVF market till 2020 and its regional shares. The ...

April 2015 70 pages

US Home Healthcare Market Outlook 2020

US$ 1,000.00

... home healthcare market is forecasted to grow at a CAGR of approximately 7% during 2015-2020. In latest research study, “US Home Healthcare Market Outlook 2020”, RNCOS’ analysts have identified the market ...

April 2015 70 pages

Harnessing the Power of Patient Support Programmes: Pharma, Patient and Payer Perspectives

US$ 595.00

... challenge of patient-centricity. Based on expert interviews, Harnessing the Power of Patient Support Programmes: pharma, patient and payer perspectivesuncovers key trends in patient relationship programs from patient, payer ... open arms. Insightful, wide ranging and compelling, Harnessing the Power of Patient Support Programmes: pharma, patient and payer perspectives offers new insights from ...

April 2015 -

Physician Views: What Scope for the Next Oral RA Therapy?

US$ 695.00

... of uptake, particularly as many KOLs expected Pfizer's drug to be priced lower. What does the performance and positioning of Xeljanz mean for other ... do you think will be necessary to drive adoption of baricitinib in favour of Xeljanz? What impact do you think availability of a cheaper, once-daily oral treatment ...

April 2015 -

Trends & Innovations Sales Force Effectiveness

US$ 595.00

... modern pharma sales representative and what skills, knowledge, tools, training and incentives will make them really effective? Trends and Innovations in Sales Force Effectiveness is an important report for anyone looking to optimise their field sales force performance. This reports offers critical insights for sales and ...

April 2015 -

Wearables for Health: Innovations and Disruptions

US$ 3,500.00

Health innovations such as wearables and their apps offer new means for consumers to manage their health and wellness. These innovations also disrupt traditional health and ... . This report examines new wearable products from multiple perspectives, analyzing consumer use cases for health and wellness management and care ...

April 2015 68 pages

Physician Views: Is Esperion's ETC-1002 a Viable Threat to the PCSK9 Inhibitors if Mid-Stage Data are Replicated in Phase III Studies?

US$ 695.00

... Esperion Therapeutics release promising Phase IIb data for its oral hypercholesterolaemia treatment ETC-1002. When added to stable statin therapy, a 180mg dose of ETC-1002 ... . Esperion CEO Tim Mayleben was in a bullish frame of mind as data for ETC-1002 broke last week, proclaiming the drug to represent a "patient friendly, physician ...

March 2015 -

Physician Views: How Comfortable are Doctors with the Commercial Use of Gene Therapy?

US$ 695.00

... safety issues first emerged? To gain better understanding about the views of doctors on the potential of gene therapy, FirstWord PLUS is polling US- and ... launched in Germany at a price of more than 1 million euros ($1.1 million). How concerned are you that gene therapies like this may prove cost ...

March 2015 -

Metabolic Testing Market by Product (CPET, Body Composition Analysis, ECG, Portable System), by Application (Critical Care, Lifestyle Diseases), by Technology (REE, Body Composition Analysis), by End User (Gym, Sports, Hospital) - Global Forecast to 2019

US$ 3,390.00

... : Product Development: Product portfolios of the top players in the metabolic testing market. Detailed insights on upcoming technologies, research and development activities, and new product launches in the metabolic testing market Competitive Assessment: In-depth assessment of market shares, strategies, geographic and business segments, and product portfolios of the leading players in the metabolic testing market Market ...

March 2015 148 pages

Physician Views: Will PEGASUS Data Make AstraZeneca's Brilinta Fly?

US$ 695.00

... data from AstraZeneca's PEGASUS-TIMI 54 study this weekend, their remains mixed views as to whether trial results will ... the PEGASUS study - noted that Plavix use in this setting is evidence that physicians ... do they think the PEGASUS data are? Whether they think the PEGASUS data will have an indirectly positive ...

March 2015 -

2014 Sales of Recombinant Therapeutic Antibodies & Proteins

US$ 140.00

2014 Sales of Recombinant Therapeutic Antibodies & Proteins This Competitive Intelligence report prepared by La Merie Business Intelligence provides a compilation of the sales data of recombinant therapeutic proteins and antibodies in the calendar year 2014. Sales data were obtained from company publications ...

March 2015 39 pages

Engineered TCR and CAR Immunotherapeutics 2015

US$ 2,630.00

... Engineered TCR and CAR Immunotherapeutics 2015: A comparative analysis of the landscape of and business opportunities with  TCR and CAR antibodies, T cells, NK cells, TILs, DLIs & CTLs The engineered ... Cellular TCR T Cells CAR T Cells (autologous/allogeneic) Recombinant Bispecific TCR-anti-CD3 (e.g. ImmTACs) Bispecific antibodies (incl. anti-CD3) This report Engineered TCR and CAR Immunotherapeutics ...

March 2015 201 pages

Physician Views: What Impact Will New Kyprolis Data Have on MM Treatment Paradigm?

US$ 695.00

... What’s more, Amgen will soon be looking at the possibility of facing additional competition from several oral proteasome inhibitors, which will ... . Porges is taking more optimistic view of Amgen's prospects and thinks Kyprolis ... much of an impact the ENDEAVOR results are likely to have with physicians, and whether ...

March 2015 -

Physician Views – Defining a Suitable NASH Therapy

US$ 695.00

... characteristics for an ideal NASH therapy, as based on KOL feedback. This Physician Views poll uses that summary as inspiration and asks US and EU5 ...

March 2015 -

Competitor Analysis: IDO & TDO Inhibitors - Novel Immune Response Checkpoint Modulators

US$ 185.00

... Competitor Analysis: IDO & TDO Inhibitors - Novel Immune Response Checkpoint Modulators The Competitive Intelligence report about IDO & TDO Inhibitors - Novel Immune Response Checkpoint Modulators provides a competitor analysis as of March 2015 in the development pipeline of novel inhibitors of indoleamine 2,3-dioxygenase (IDO) and ...

March 2015 18 pages

Saudi Arabian Healthcare Outlook 2020

US$ 1,200.00

... healthcare projects. The government intends to significantly increase the quality of healthcare services in the country. As per our latest research report “Saudi Arabian Healthcare Outlook 2020”, the healthcare ...

March 2015 115 pages

Telemedicine and Mobile Healthcare Solutions, Services, and Devices: Market Analysis and Forecasts 2015 - 2020

US$ 1,995.00

Telemedicine, Tele-health, M-Health and Connected Health are all terms that pertain to the use of telecommunications and information technology in order to provide remote clinical/non-clinical healthcare ...

March 2015 175 pages

Nonalcoholic Steatohepatitis: KOL Insight

US$ 7,495.00

... of nonalcoholic steatohepatitis (NASH) as a number of new therapies compete to become the first approved treatment for a disease that has high unmet clinical need. Nonalcoholic Steatohepatitis: KOL Insight reveals the critical views of US and European KOLs whose insights hold key lessons for pharma. Gain insights on products in the ...

March 2015 -

Payer Perspectives on Risk Sharing Deals

US$ 595.00

... , risk-averse marketplace. Are you up to speed on all that a risk sharing agreement might do for your product or organization? Payer Perspectives on Risk Sharing offers expert insights on how risk sharing agreements can be a win-win for both pharmaceutical companies and payers in helping to build ...

March 2015 -

FirstView Barriers – An Analysis of Market Barriers in Multiple Sclerosis (EU5)

US$ 4,995.00

FirstView Barriers – An Analysis of Market Barriers in Multiple Sclerosis (US) provides cutting edge, advanced and proprietary analytics ... the major markets of Europe – France, Germany, Italy, Spain, the UK prescribing to their MS patients? What is the top market barrier that forces a physician ...

March 2015 -

FirstView Barriers – An Analysis of Market Barriers in Multiple Sclerosis (US)

US$ 4,995.00

FirstView Barriers – An Analysis of Market Barriers in Multiple Sclerosis (EU5) provides cutting edge, advanced and proprietary ... your brand is getting share from. The proprietary barrier instrument utilizes statistical analysis and advanced calculation to provide you with this precise ...

March 2015 -

Trends and Innovations in Patient Adherence

US$ 595.00

... do so many patients fail to adhere to their treatment programme? Trends and Innovations in Patient Adherenceis a thought-provoking and comprehensive report for everyone involved in ensuring patients comply ... Chief pharmacist, Spain Anonymous German KOL Patient Opinion Leaders Director, European Patients’ Academy on Therapeutic Innovation (EUPATI) Board member of the European Parkinson ...

March 2015 -

Global Dialysis Market Report: 2015 Edition

US$ 800.00

... out either by dialysis or kidney transplant. The report analyzes the global and regional dialysis markets. Some of the factors driving the growth of dialysis market include: growing number ...

February 2015 47 pages

North America Laboratory Information System Market

US$ 3,390.00

... laboratory information system is customized as per the laboratory requirements. Advancements made in the healthcare IT sector have influenced the overall demand of such innovative clinical information systems, globally. North America ... market impetus that augments the overall demand of the laboratory information system market in North America. The North American laboratory information systems market is segmented on the basis of geography, product, application ...

February 2015 150 pages

Physician Views: Pfizer delivered regulatory promise with Ibrance, can it deliver a strong launch?

US$ 695.00

... date, has vindicated the company's bullish stance on delivering the drug to market (ViewPoints: Pfizer sets out – earlier than expected – to show value ... evenly as to whether they thought Phase II results were sufficient to support regulatory clearance. A key question is whether this reticence will curb uptake ...

February 2015 -

Competitor Analysis: Specific and Bispecific Her3 Antibodies

US$ 260.00

Competitor Analysis: Specific and Bispecific Her3 Antibodies This Competitive Intelligence Report about Specific and Bispecific Her3 Antibodies provides a competitor evaluation in the field of recombinant specific antibodies targeting Her3 or bispecific antibodies targeting Her3 and Her2 or EGF-R or other ...

February 2015 27 pages

Physician Views: The return of inhaled insulin – a paradigm shift or hard sell?

US$ 695.00

... include likely broad tier-3 formulary status at launch and the view among some analysts that endocrinologists will not proactively prescribe ... are discouraged to initiate insulin therapy due to injectable administration, while physician feedback sourced by FirstWord indicates that patients with needle phobia ...

February 2015 -

Physician Views: How will US-based endocrinologists use Eli Lilly, Boehringer Ingelheim's newly approved Glyxambi?

US$ 695.00

... of the SGLT-2 class is likely to have reinforced this view. Reflecting an initially cautious view among analysts towards the SGLT-2 inhibitor class, consensus ... and what impact will the combination have on both the SGLT-2 and DPP-4 classes? To better understand we are polling US-based endocrinologists, asking ...

February 2015 -

Physician Views: Ofev approved, Esbriet label updated – what impact on IPF-treating pulmonologists in the EU5?

US$ 695.00

... has been in the US where both Ofev and Esbriet were approved in the fourth quarter of 2014 (Esbriet was approved in Europe during 2011, but InterMune was required to carry out additional Phase III studies to secure US clearance). See Physician Views ...

February 2015 -

Hospital Information System Market in India 2015

US$ 950.00

... in 0-2 business days after order is placed. Netscribes’ latest market research report titled Hospital Market in India 2014 captures the largest segment of the overall domestic ...

February 2015 108 pages

Global Peptide Therapeutics Pipeline Insight 2015

US$ 2,400.00

... size ... Peptide & Insulin “Global Peptide Therapeutics Pipeline Insight 2015” Report Highlights: Global Peptide Therapeutics Market Overview Global Peptide Therapeutics Pipeline By Peptide Type Global Peptide Therapeutics Pipeline By Company, Indication & Phase Peptide Therapeutics Clinical Pipeline: 743 Peptides ...

February 2015 1200 pages

Filters

Search

Categories

1,254
193
212
1,214
34
241
217
160
142
64,306
1,332
1,265
2,373
185

Publishers

649
541
179
32
1
1,509
34
239
366
389
103
148
348
3
202
3
6
1,623
487
80
123
208
112
31
1,049
383
23
40
68
513
953
34
29,954
248
501
3,036
1
1
2
3
16
536
361
1
1,357
1,806
60
1,696
8
7,373
2,206
6,530
321
66
3
36
200
29
29
143
42
83
3
281
85
20
6
43
14
1
178
48
359
36
44
10
11
18
168
385
8
3
18
58
913
6
89
12
24
15
1,286
229
128
386
3
74
10
119
227
46
474
26
133
4

Regions

201
97
86
75
74
50
48
42
41
40
36
36
35
31
30
29
28
27
27
26
24
24
18
17
17
17
17
16
16
15
13
12
12
11
10
9
8
8
8
7
7
6
6
6
6
5
4
4
4
4
3
3
3
3
3
3
3
3
3
3
3
3
3
3
3
3
3
3
3
3
3
3
3
3
3
3
3
3
3
3
3
3
3
3
3
3
3
3
3
3
3
2
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
798
552
2
2
2
118
198
104
61
38
709
75
136
531
215
1,137
66,824

Price

—

Date

—

Pages

—

Offers

1
280
1
1